The Overview
AbbVie announced positive primary results from the Phase 2 APEX Part B study of zumilokibart in 346 adult patients with moderate to severe atopic dermatitis. All three tested dose regimens of the IL-13 inhibitor met the primary endpoint, demonstrating significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response rates compared to placebo at Week 16. The mid-dose regimen, which also showed rapid improvements in skin severity and itch, has been selected for further evaluation in Phase 3 development, supporting its potential as a differentiated long-term therapy.
Knolens Analysis
At a Glance
| Indication | moderate to severe atopic dermatitis |
| Drug | Zumilokibart |
| Mechanism of Action | IL-13 inhibitor |
| Company | AbbVie |
| Trial Phase | Phase 2 |
| Trial Acronym | APEX Part B |
| NCT ID | NCT07003425 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Immunology |
| Primary Endpoint | proportion of participants achieving at least a 75% improvement from baseline in EASI (EASI-75) at Week 16 |
| Secondary Endpoints | EASI 90/100, I-NRS |
| Patient Population | adult patients with moderate to severe atopic dermatitis |
| Number of Participants | 346 |
| Study Design | randomized, double-blinded, placebo-controlled, dose-finding study |
| Treatment Arms | low-, mid-, high-dose zumilokibart regimen, placebo |
| Follow-up Duration | 16-week induction period |
| Conference Name | 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress |
| Presentation Date | Wednesday, September 30, 2026; 4:15 p.m. CEST |
| Common Adverse Events | nasopharyngitis, headache, noninfective conjunctivitis, upper respiratory tract infection, atopic dermatitis, urinary tract infection |
| Drug Half-life | approximately 77 days |
AbbVie's Zumilokibart Shows Positive Phase 2 Results in Atopic Dermatitis
AbbVie announced positive primary results from the Phase 2 APEX Part B study of zumilokibart in 346 adult patients with moderate to severe atopic dermatitis. All three tested dose regimens of the IL-13 inhibitor met the primary endpoint, demonstrating significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response rates compared to placebo at Week 16. The mid-dose regimen, which also showed rapid improvements in skin severity and itch, has been selected for further evaluation in Phase 3 development, supporting its potential as a differentiated long-term therapy.
- All three zumilokibart dose regimens (low, mid, high) achieved the primary endpoint of EASI-75 response at Week 16, showing statistically significant improvements over placebo. The mid-dose regimen, which was identical to the induction regimen in APEX Part A, has been chosen for advancement into Phase 3 development, underscoring its potential for long-term treatment.
- Beyond the primary endpoint, the mid- and high-dose regimens demonstrated significantly greater improvements across key secondary endpoints, including near-complete or complete skin clearance (EASI 90/100) and itch reduction (I-NRS) compared to placebo. Notably, the mid-dose regimen showed rapid onset of action, with greater reductions in skin severity at Week 1 and itch at Week 2.
- Zumilokibart, a half-life extended monoclonal antibody targeting IL-13, exhibited a safety profile consistent with previous findings. The most common treatment-emergent adverse events were nasopharyngitis, headache, noninfective conjunctivitis, upper respiratory tract infection, atopic dermatitis, and urinary tract infection. Its extended half-life of approximately 77 days supports the potential for convenient dosing intervals, addressing an unmet need for long-term AD therapies.
Frequently Asked Questions
What is considered moderate to severe atopic dermatitis?
Moderate to severe atopic dermatitis (AD) is characterized by extensive body surface area (BSA) involvement, typically exceeding 10% to 20%, and significant disease activity. This is often reflected in objective severity scores such as an Eczema Area and Severity Index (EASI) score of ≥7 or an Investigator's Global Assessment (IGA) score of ≥3. Patients experience substantial impact on quality of life, including severe pruritus, sleep disturbance, and psychological distress, often despite adequate topical therapy.
What is zumilokibart?
Zumilokibart is an investigational human monoclonal antibody that targets OX40 ligand (OX40L). By binding to OX40L, it aims to inhibit the OX40/OX40L co-stimulatory pathway, thereby modulating T-cell activation and reducing inflammation. It is currently being evaluated in clinical trials for the treatment of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.
What is the miracle shot for eczema?
Dupilumab (Dupixent) is widely considered a breakthrough "miracle shot" for moderate-to-severe atopic dermatitis. This biologic targets the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, effectively reducing the underlying type 2 inflammation. Its efficacy has significantly improved disease control and quality of life for many patients unresponsive to conventional therapies.
Can atopic dermatitis go away permanently?
Atopic dermatitis is a chronic inflammatory skin condition characterized by periods of flares and remission. While many individuals, particularly children, may experience prolonged symptom-free periods, the underlying immune dysregulation and genetic predisposition persist, meaning it is generally not considered to "go away permanently" in the sense of a cure. Recurrence is possible throughout life, necessitating ongoing management strategies to control symptoms and prevent flares.
What are the latest research findings on atopic dermatitis?
Latest research emphasizes the identification of novel therapeutic targets beyond IL-4/IL-13, with investigational agents targeting TSLP, OX40, and IL-31 showing promise in clinical development. Advances in understanding disease heterogeneity are revealing distinct endotypes, driven by specific immune pathways or barrier defects, which may inform personalized treatment strategies and biomarker development. Further studies are elucidating the complex interplay of the skin microbiome in disease pathogenesis and exploring its modulation as a potential therapeutic avenue.
What is the severity score for atopic dermatitis?
There isn't a single, universal "severity score" for atopic dermatitis; instead, multiple validated tools are used to assess its severity. Key objective measures include the Eczema Area and Severity Index (EASI) and SCORing Atopic Dermatitis (SCORAD), which are widely used in clinical trials. The Investigator's Global Assessment (IGA) provides a simpler, physician-rated scale, while patient-reported outcomes like the Patient-Oriented Eczema Measure (POEM) capture subjective burden.
What are the results of the Dupixent clinical trials?
Dupixent clinical trials consistently demonstrated significant efficacy across its approved indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Key results include substantial improvements in disease severity scores (e.g., EASI, IGA), reduced exacerbation rates, improved lung function (FEV1), histological remission, and significant pruritus reduction. These outcomes highlight its targeted inhibition of IL-4 and IL-13 signaling, leading to broad anti-inflammatory effects.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
